Philippe Legenne
Impact in
- Otorhinolaryngology top 5%
- Head and Neck Cancer Studies
- Oncology top 10%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
Papers in
- Oncology 20
- Peptidase Inhibition and Analysis 6
- HER2/EGFR in Cancer Research 5
- Lung Cancer Research Studies 4
- Cancer Immunotherapy and Biomarkers 4
- Cancer Treatment and Pharmacology 3
-
- Lung Cancer Treatments and Mutations 7
- Co-authors
- Stephen Lane (6 shared papers)Georgina V. Long (5 shared papers)Jean‐Jacques Grob (3 shared papers)Caroline Robert (2 shared papers)Dirk Schadendorf (2 shared papers)Antoni Ribas (2 shared papers)Carmen Mak (2 shared papers)Michael A. Davies (3 shared papers)
- Journals
- Journal of Clinical Oncology (11 papers)European Journal of Cancer (2 papers)Blood (2 papers)Cancer Research (1 paper)British Journal of Cancer (1 paper)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Philippe Legenne
28 papers receiving 501 citations
Peers
Comparison fields: 5 of 53
- Otorhinolaryngology 78
- Oncology 362
- Molecular Biology 287
- Pulmonary and Respiratory Medicine 119
- Cancer Research 35
Countries citing papers authored by Philippe Legenne
This map shows the geographic impact of Philippe Legenne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Legenne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Legenne more than expected).
Fields of papers citing papers by Philippe Legenne
This network shows the impact of papers produced by Philippe Legenne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Legenne. The network helps show where Philippe Legenne may publish in the future.
Co-authors
The 25 scholars most cited alongside Philippe Legenne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 212 | |
| 2 | 2012 | 89 | |
| 3 | Lack of activity of amphotericin B in systemic murine fusarial infection. | 1992 | 46 |
| 4 | 2013 | 29 | |
| 5 | 2020 | 25 | |
| 6 | 2010 | 21 | |
| 7 | 2015 | 19 | |
| 8 | 2014 | 19 | |
| 9 | 2010 | 6 | |
| 10 | 2022 | 5 | |
| 11 | 2013 | 5 | |
| 12 | 2016 | 5 | |
| 13 | 2024 | 4 | |
| 14 | 2024 | 4 | |
| 15 | 2023 | 3 | |
| 16 | 2023 | 3 | |
| 17 | 2023 | 3 | |
| 18 | 2013 | 3 | |
| 19 | 2024 | 2 | |
| 20 | 2025 | 2 |
About Philippe Legenne
Philippe Legenne is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Hematology, having authored 29 papers that have together received 516 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (7 papers), Peptidase Inhibition and Analysis (6 papers), Melanoma and MAPK Pathways (5 papers), HER2/EGFR in Cancer Research (5 papers), Lung Cancer Research Studies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Cancer Treatment and Pharmacology (3 papers) and Protein Degradation and Inhibitors (3 papers). The work is most often cited by research in Otorhinolaryngology (78 citations), Oncology (362 citations), Molecular Biology (287 citations), Pulmonary and Respiratory Medicine (119 citations) and Cancer Research (35 citations). Philippe Legenne has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Stephen Lane, Georgina V. Long, Jean‐Jacques Grob, Caroline Robert, Dirk Schadendorf, Antoni Ribas, Carmen Mak, Michael A. Davies, Keith T. Flaherty and Paul Nathan. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Blood, Cancer Research and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.